EVALUATION OF IMMUNOGENICITY AND PTOTECTIVENESS OF THE VACCINIA VIRUS LIVP-GFP IN THREE LABORATORY ANIMAL SPECIES
Smallpox eradication and absence of adequate animal model of smallpox infection causes necessity of the assessment of immunogenic and protective properties of the created by genetic engineering approaches live attenuated smallpox vaccines in several animal models of orthopoxviral infections. In this...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
Sankt-Peterburg : NIIÈM imeni Pastera
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/17d2e853962c420fbeea6584152ca8e6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Smallpox eradication and absence of adequate animal model of smallpox infection causes necessity of the assessment of immunogenic and protective properties of the created by genetic engineering approaches live attenuated smallpox vaccines in several animal models of orthopoxviral infections. In this research comparison of the immunogenic and protective properties of the recombinant vaccinia virus (VACV) LIVP-GFP after intradermal (i/d) injection to mice, guinea pigs and rabbits were carried out. Doses of LIVP-GFP immunization in all animal species were 2x104 or 2x106 pfu. Control animals were injected with saline. Blood sampling was done on 28 day after virus LIVP-GFP or saline injection. Blood samples were taken intravitally from the retro-orbital venous sinus of mice, from heart of guinea pigs or marginal ear vein of rabbits. Serum was isolated from blood samples by precipitating blood cells via centrifugation. The anti-VACV IgG titers in the serum samples were determined by ELISA. On 30 day of the experiment immunized by virus LIVP-GFP or control animals were intranasal infected with lethal doses of the corresponding orthopoxviruses to which every animal species was sensitive. Mice were infected by cowpox virus (CPXV) strain GRI-90 in dose 68 LD50, guinea pigs - by VACV GPA in dose 56 LD50, rabbits – by VACV HB-92 in dose 100 LD50. All control animals after that were died, but all animals immunized by attenuated recombinant virus LIVP-GFP in dose 2x106 pfu were survived. In case of the LIVP-GFP immunization dose 2x104 pfu 88% of mice were survived after CPXV infection, 67% of rabbits were survived after VACV HB-92 infection, and 50% of guinea pigs were survived after VACV GPA infection. ELISA data of the blood serums had shown correlation of the levels of VACV-specific antibodies with levels of protection in the corresponding animals. On the basis of the obtained data it could be concluded that all three studied models animal-orthopoxvirus allow give an adequate evaluation of immunogenicity and protectiveness of the created modern attenuated vaccines against smallpox and other orthopoxviral human infections. BALB/c mice are the most convenient subject of this investigation |
|---|